Literature DB >> 31865206

Performance evaluation of a MIP for the MISPE-LC determination of p-[18F]MPPF and a potential metabolite in human plasma.

F Lecomte1, J Aerts2, A Plenevaux2, C Defraiteur2, F Chapuis-Hugon3, E Rozet4, P Chiap5, A Luxen2, V Pichon6, Ph Hubert1, C Hubert7.   

Abstract

Within the family of serotonin (5-HT) receptors, the 5-HT1A subtype is particularly interesting as it may be involved in various physiological processes or psychological disorders. The p-[18F]MPPF, a highly selective 5-HT1A antagonist, is used for in vivo studies in human or animal by means of positron emission tomography (PET) [1]. In order to selectively extract p-[18F]MPPF and its main metabolites from plasma, molecularly imprinted polymer (MIP) was prepared against these compounds by using the p-MPPF as template. For the control of the selectivity, non-imprinted polymer (NIP) was also synthesized without template. The MIP sorbent, packed in disposable extraction cartridges (DECs), was then evaluated as molecularly imprinted solid-phase extraction (MISPE) prior to the LC determination. The conditions of extraction were evaluated in order to obtain the highest selective retention of the p-[18F]MPPF and its metabolites on this MIP. The MIP selectivity was exploited in the loading and washing steps by adjusting the pH of plasma samples at a suitable value and by selecting mixtures for the washing step to limit the contribution of non-specific interactions. Other important parameters involved in the conditioning and elution steps were also studied. Finally, a pre-validation was carried out with optimal extraction conditions to demonstrate the performance of this MISPE-LC method as a generic method in the context of evaluation of new MISPE for p-[18F]MPPF and its potential for metabolites extraction from human plasma.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MIP; Molecularly imprinted polymer; Plasma sample; Radiopharmaceutical compound; Solid-phase extraction; p-MPPF

Mesh:

Substances:

Year:  2019        PMID: 31865206     DOI: 10.1016/j.jpba.2019.113015

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia.

Authors:  Jiao Wang; Wenxin Qi; Hongwei Shi; Lin Huang; Fujiang Ning; Fushuai Wang; Kai Wang; Haotian Bai; Hao Wu; Junyi Zhuang; Huanle Hong; Haicong Zhou; Hu Feng; Yinping Zhou; Naijun Dong; Li Liu; Yanyan Kong; Jiang Xie; Robert Chunhua Zhao
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.